A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
NCT07629115 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6
Last updated 2026-07-01
Summary
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Conditions
- Parkinson Disease
- Parkinson's Disease
Sponsors & Collaborators
-
Innopeutics Corporation
lead INDUSTRY
Eligibility
- Min Age
- 50 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-29
- Primary Completion
- 2031-07-30
- Completion
- 2031-10-30
Countries
- South Korea
Study Locations
More Related Trials
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650 ·Status: TERMINATED ·Phase: PHASE2
-
Long Term Follow-up of Patients With Parkinson's Disease Who Had Administered of A9-DPC in SB-PD-001 Study
NCT06477744 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety and Effectiveness of Intermittent Hypoxia Treatment in Parkinson's Disease
NCT05948761 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus
NCT07533591 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations
NCT07585565 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of GM101 Injection in Patients With Parkinson's Disease
NCT07100171 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
NCT02562768 ·Status: COMPLETED ·Phase: PHASE1
-
Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease
NCT06821529 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
NCT05603312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
NCT06167681 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
NCT07195825 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
NCT04056689 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
NCT07414290 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Drug Interaction With Genes in Parkinson's Disease
NCT01564992 ·Status: UNKNOWN
-
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
NCT01523301 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
NCT07685444 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
NCT06175767 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
NCT04295642 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
NCT07566429 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase 2a Study of VTX3232 in Parkinson's Disease
NCT06556173 ·Status: COMPLETED ·Phase: PHASE2
-
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
NCT00209508 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
NCT07617012 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
NCT00056563 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
NCT01603069 ·Status: COMPLETED ·Phase: PHASE2